Automating Pharmacovigilance Intake Workflows: A Practical Guide to Adverse Event Reporting for Life Sciences

The Shift from Cost Control to Quality Assurance

A decade ago, as adverse event reporting workloads began to soar, many pharmaceutical companies responded by outsourcing and then offshoring pharmacovigilance activities. The associated cost savings were real, but over time they often came at the expense of data quality and internal oversight. In recent years, a growing number of companies have sought to rebuild internal capabilities, even at higher cost and amid a persistent talent shortage, by harnessing smarter technology rather than cheaper labor.

Today, the emphasis on quality is reflected in specific automation goals. Thirty-five percent of surveyed professionals identified improved data quality as the chief objective of pharmacovigilance automation, rising to 40 percent among those in drug safety roles. For speed-related improvements, accelerated processing was the main benefit sought, cited by 34 percent of respondents and 38 percent of drug safety teams, who also emphasized prompter reporting. Notably, product safety teams were the most likely to target reduced infrastructure costs and the least likely to view automation as a means of labor replacement. The prevailing view treats automation as a way to augment existing staff, allowing experienced professionals to focus on higher-value activities such as signal investigation, risk management, and medical assessment rather than repetitive data entry.

Where Automation Currently Stops Short

Despite strong intentions - up to two-thirds of companies claim to have pharmacovigilance automation solutions already in place or likely to implement them within twelve months - the reality is often more limited. When surveyed, 42 percent of respondents claimed to have automated adverse event reporting in operation, yet much of this automation refers to isolated functions rather than end-to-end case processing. Common examples include auto-scheduling reports for regulatory submission, generating auto-narratives, and using electronic data capture tools that are bundled within existing safety vendor platforms. These features are useful, but they tend to add incremental value rather than transform the core workflow of case collection, database work, triage, and reporting.

The COVID-19 pandemic stalled some digital transformation programs, though only two percent of organizations curtailed automation projects completely. Nevertheless, the proportion of companies with substantive automation in place remained largely flat from 2020 to 2021, even though roughly 40 percent had previously expected to introduce new solutions. The gap between ambition and execution persists, in part because of two lingering barriers: fear of job displacement among staff and the complexity of system validation in a highly regulated environment.

What It Actually Takes to Automate Pharmacovigilance Intake Workflows

To move beyond fragmented point solutions, organizations need to treat intake as an integrated workflow rather than a simple data-entry step. The process begins with multi-channel case collection - gathering submissions from healthcare professionals, patients, clinical sites, call centers, and regulatory agencies in formats that range from structured electronic fields to unstructured emails and scanned documents. Artificial intelligence and machine learning can extract relevant safety case attributes from both structured and unstructured sources, perform consistency checks, and populate the safety database with minimal manual transcription.

Conceptually, this is similar to electronic data capture in clinical trials, where reporters enter information directly into a system rather than routing it through layers of manual transcription. The goal is to let reporters input data once, directly into the pharmacovigilance database, circumventing redundant data-entry effort while preserving accuracy. Once captured, cases can be routed through triage, medical review, quality review, and submission preparation in a more streamlined sequence.

When automation is applied across intake and assessment, review, full data entry, medical review, quality review, and submission, leading safety teams have reported efficiency gains of up to 80 percent through touchless case processing.

Technical and Compliance Requirements

Implementing intake automation in a regulated environment demands more than software deployment. Safety teams should evaluate solutions against several concrete criteria.

Not all safety platforms offer proven, pre-validated automation in production. Distinguishing between a vendor’s bundled feature and a purpose-built, validated model is a critical step in procurement.

• First, data quality is foundational. The information used to train and validate automation models must be accurate and representative, because model output is only as reliable as the input that shaped it.
• Second, the system must account for the variety of fields, formats, and sources that characterize real-world adverse event reporting.
• Third, explainability is non-negotiable. Automation cannot function as a black box; teams must be able to communicate how decisions were made, maintain a clear audit trail, and satisfy regulatory inspectors.
• Fourth, model training and validation should not be treated as afterthoughts. Organizations can reduce implementation risk by using pre-trained models built on industry-relevant data, provided those models have been thoroughly validated prior to going live.
• Finally, the system should be designed for continuous improvement, gaining incremental accuracy as it encounters new data rather than degrading over time.

Outcomes and Resource Reallocation

When intake automation is executed strategically, the benefits extend beyond speed. Process consistency improves because automated extraction and validation reduce the probability of human error and standardize complex workflows. Resource utilization improves because experienced professionals can be shifted from transcription and formatting to safety monitoring, risk reduction, and proactive signal detection. Scalability improves because the infrastructure can absorb rising case volumes - whether from new specialty drugs, additional geographic markets, or expanded surveillance channels - without a linear increase in headcount.

This scalability is particularly important given that global pharmacovigilance spending is anticipated to grow at a compound annual rate of 11.5 percent through 2028. Companies that treat automation as a quality and scalability initiative, rather than a narrow cost-cutting exercise, are better positioned to handle the next wave of reporting volume without compromising compliance or patient safety.

A Practical Path Forward

Organizations beginning this transition should start with an honest audit of their current state. Identify where automation is truly end-to-end and where it is limited to isolated tasks such as literature screening, auto-narrative generation, or document compilation. Because intake underpins every subsequent pharmacovigilance activity, it offers the highest leverage for improvement.

Next, evaluate whether candidate solutions offer pre-validated models trained on diverse, industry-relevant safety data, and confirm that the architecture supports explainability and auditability. Address organizational barriers directly: validation concerns should be met with clear documentation and risk-based qualification strategies, while staff concerns should be addressed by framing automation as a tool that handles repetitive intake tasks so that specialists can concentrate on clinical judgment and safety analysis.

For teams operating between fragmented vendor tools and full end-to-end transformation, custom workflow automation can bridge the gap. CEDX Systems builds intake automations that connect multi-channel case sources directly to existing safety databases and regulatory submission workflows, designed around validation requirements rather than forcing teams to adapt to rigid, one-size-fits-all platforms. By integrating with the systems already in place, this approach preserves prior technology investments while closing the manual gaps that slow down adverse event processing.

Conclusion

The next phase of pharmacovigilance will be defined by how effectively organizations handle the first mile of case processing. Treating automation as a quality imperative - one that demands explainable models, rigorous validation, and respect for existing regulatory workflows - allows life sciences companies to manage growing adverse event volumes without sacrificing data integrity. Those that invest in robust intake automation now will be equipped to scale their safety operations proactively, keeping patient protection at the center of every reporting decision.